Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 15/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 12/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 12/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.57 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.57 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | CYP3A43 | Q9HB55 | 1/20 | 0.57 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.57 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.54 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.54 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.54 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30503871 | 1.00 | CYP3A4 (0.57) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| SCHEMBL30503833 | 1.00 | CYP3A4 (0.57) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| SCHEMBL28083220 | 1.00 | CYP3A4 (0.57) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| SCHEMBL30503797 | 1.00 | CYP3A4 (0.57) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| SCHEMBL30503809 | 1.00 | CYP3A4 (0.57) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| SCHEMBL3368908 | 0.91 | CYP3A4 (0.68) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| SCHEMBL9714198 | 0.91 | CYP3A4 (0.68) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| SCHEMBL3372668 | 0.90 | CYP3A4 (0.56) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| SCHEMBL29058727 | 0.88 | CYP3A4 (0.54) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| Oxalic Acid SCHEMBL3444375 | 0.88 | CYP3A4 (0.53) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105801500-A | Method for resolving racemic body of intermediate compound of Isavuconazole | 四川科伦药物研究院有限公司 | 2016-07-27 | — | — | CN | disclosed |
| US-8207352-B2 | Process for the manufacture of enantiomerically pure antifungal azoles as ravuconazole and isavuconazole | Drug Process Licensing Associates LLC (US) | 2012-06-26 | — | — | US | disclosed |
| US-8207352-B2 | Process for the manufacture of enantiomerically pure antifungal azoles as ravuconazole and isavuconazole | Drug Process Licensing Associates LLC (US) | 2012-06-26 | — | — | US | disclosed |
| US-20110087030-A1 | Process for the manufacture of enantiomerically pure antifungal azoles as ravuconazole and isavuconazole | Carbo-Design LLC | 2011-04-14 | — | — | US | disclosed |
| US-20110087030-A1 | Process for the manufacture of enantiomerically pure antifungal azoles as ravuconazole and isavuconazole | Carbo-Design LLC | 2011-04-14 | — | — | US | disclosed |
| EP-1399402-B1 | INTERMEDIATE HALOPHENYL DERIVATIVES AND THEIR USE IN A PROCESS FOR PREPARING AZOLE DERIVATIVES | BASILEA PHARMACEUTICA AG (CH) | 2010-09-29 | — | — | EP | disclosed |
| US-7115643-B2 | Intermediate halophenyl derivatives and their use in a process for preparing azole derivatives | BASILEA PHARMACEUTICA AG (CH) | 2006-10-03 | — | — | US | disclosed |
| US-20040176432-A1 | Intermediate halophenyl derivatives and their use in a process for preparing azole derivatives | BASILEA PHARMACEUTICA AG (CH) | 2004-09-09 | — | — | US | disclosed |
| EP-1399402-A1 | INTERMEDIATE HALOPHENYL DERIVATIVES AND THEIR USE IN A PROCESS FOR PREPARING AZOLE DERIVATIVES | Basilea Pharmaceutica AG (CH) | 2004-03-24 | — | — | EP | disclosed |
| WO-2003002498-A1 | INTERMEDIATE HALOPHENYL DERIVATIVES AND THEIR USE IN A PROCESS FOR PREPARING AZOLE DERIVATIVES | BASILEA PHARMACEUTICA AG (CH) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110087030-A1 | Process for the manufacture of enantiomerically pure antifungal azoles as ravuconazole and isavuconazole | CYP51A1, ERG28, CYP3A4 | CYP3A4 3/4885CYP2C9 18/4885CYP2C19 13/4885 |
| US-20040176432-A1 | Intermediate halophenyl derivatives and their use in a process for preparing azole derivatives | CYP51A1, MALT1, CYP7A1 | CYP3A4 42/4885CYP2C9 60/4885CYP2C19 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.